TILT Biotherapeutics Revenue and Competitors

TILT Biotherapeutics Ltd is a clinical stage company working in the area of enabling tumor T-cell therapy and checkpoint inhibitors with oncolytic viruses. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR-T therapy of solid tumors as currently achieved for CD19+ hematological tumors. TILT was founded by Pr. Akseli Hemminki, who has published hundreds of papers in the field and treated almost 300 patients with 10 different oncolytic viruses. In 2013 Pr. Hemminki started his second company, TILT Biotherapeutics, which technology is based on his past findings in the lab, and more importantly in the clinic. The research conducted by TILT alone or in collaboration with some of world's leading research groups with synergic technologies has generated very good results. The lead candidate is a clinical stage TNFα/IL2 armed oncolytic adenovirus (TILT-123 or Ad5/3-E2F-delta24-hTNFα-IRES-hIL2). The first trial will take place in Europe and address metastatic melanoma in combination with TILs. Additional trials in other solid tumor indications are planned in combination with a checkpoint modulator and a CAR-T product. For contact: aino (at) tiltbio.com